Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism

European Journal of Nuclear Medicine

Volumn 26, Issue 2, 1999, Pages 171-182

  Booij, Jan ^a,b,c   Tissingh, Gerrit ^b   Winogrodzka, Ania ^b   Van Royen, Eric A ^a  

^a Amsterdam University Medical Center   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Dopamine D2 receptor imaging; Dopamine transporter imaging; Parkinsonism; Positron emission tomography; Single photon emission tomography

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ALTROPANE; COCAINE DERIVATIVE; DOPA; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; EPIDEPRIDE; LEVODOPA; METHYLPHENIDATE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROPROTECTIVE AGENT; RACLOPRIDE; SELEGILINE; SPIPERONE DERIVATIVE; TECHNETIUM 99M; TETRABENAZINE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DYSTONIA; ESSENTIAL TREMOR; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE D2; RECEPTORS, PRESYNAPTIC; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032998864     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050374     Document Type: Review

References (132)

1. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-681.
2. Quinn N. Multiple system atrophy - the nature of the beast [review]. J Neurol Neurosurg Psychiatry 1989; 52 (Suppl): 78-89.
3. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993; 43 (Suppl 6): S6-S16.
4. Alexander GE, Crutcher MD, DeLong MR. Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" function. In: Uylings HBM, van Edin CG, de Bruin JPC, Corner MA, Feenstra MGP, eds. Progress in brain research, vol 85. New York: Elsevier Science Publishers; 1990: 119-146.
5. 18F]fluoro-dopa, an analogue of dopa, and its use in direct measurements of storage, degeneration, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978; 75: 464-467.
6. Garnett ES, Firnau G, Nahmias C. Dopamine visualised in the basal ganglia of living man. Nature 1983; 305: 137-138.
7. 11C-nomifensine and positron emission tomography. Acta Neurol Scand 1987; 76: 283-287.
8. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine-binding sites in human and baboon brain in vivo. Synapse 1989; 4: 371-377.
9. 18F]GBR 13119. Imaging the dopamine uptake system in vivo. Nucl Med Biol 1989; 16:569-576.
10. 123I]-2β-carbomethoxy-3-β-(4-iodophenyl)tropane: high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991; 34: 3144-3146.
11. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 1993; 94: 137-146.
12. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993; 90: 11965-11969.
13. 11C]tetrabenazine and positron emission tomography. J Neurochem 1993; 60: 2315-2318.
14. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1994; 15: 1714-1723.
15. Vaughan RA, Brown VL, McCoy MT, Kuhar MJ. Species and brain region-specific dopamine transporters: immunological and glycosylation characteristics. J Neurochem 1996; 66: 2146-2152.
16. Miller GW, Staley JK, Heilman CJ, et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997; 41: 530-539.
17. Neumeyer JL, Wang S, Gao Y, et al. N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994; 37: 1558-1561.
18. 18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane and the first human study with positron emission tomography. Nucl Med Biol 1996; 23: 999-1004.
19. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 1989; 36: 518-524.
20. Kung M-P, Essman WD, Frederick D, et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 1995; 20: 316-324.
21. Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 1998; 29: 93-104.
22. 3H]WIN 35,428) in the monkey brain. Synapse 1990; 6: 189-195.
23. Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of the human brain. J Nucl Med 1996; 37: 1242-1256.
24. Seeman P, Niznik H. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990; 4: 2737-2744.
25. Hall H. Dopamine receptors: radioligands for pharmacological and biochemical characterization. In: Niznik HB, ed. Dopamine receptors and transporters: pharmacology, structure, and function. New York: Marcel Dekker; 1994: 3-33.
26. 123I [abstract]. Clinical Science 1986; 70: 53.
27. 123I in humans. Eur J Nucl Med 1990; 16: 813-816.
28. 125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 1991; 49: 617-628.
29. 123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect 1995; 101: 95-103.
30. Kung M-P, Liu B-L, Billings J, Yang Y, Murphy RA, Alavi A. The characterisation of IBF as a new selective dopamine D-2 receptor imaging agent. J Nucl Med 1990; 31: 648-654.
31. Ichise M, Ballinger JR, Vines D, Tsai S, Kung HF. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med 1997; 38: 31-37.
32. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analyses of D2-dopamine receptor binding in the living human brain by positron emission tomography. Science 1986; 231: 258-260.
33. Wagner HN, Burns HD, Dannals RF, et al. Imaging DA receptors in the human brain by PET. Science 1983; 221: 1264-1266.
34. 18F]-N-methylspiroperidol and PET. J Nucl Med 1986; 27: 1878-1882.
35. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1991; 55: 181-184.
36. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease. A clinicopathologic study. Neurology 1992; 42: 1142-1146.
37. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973; 20: 415-455.
38. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 876: 876-880.
39. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991; 9: 43-49.
40. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-860.
41. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47: 1290-1298.
42. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
43. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995; 59: 597-600.
44. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995; 45: 1995-2004.
45. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βbCIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996; 37: 1760-1765.
46. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34: 423-431.
47. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic {123I} β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
48. 123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24: 415-421.
49. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 133-140.
50. 123I]β-CIT SPECT. J Neurol 1998; 245: 14-20.
51. 18F-dopa PET in early and advanced Parkinson's disease [abstract]. Mov Disord 1996; 11: 147.
52. Clarke RL, Daum SJ, Gambino A, et al. Compounds affecting the central nervous system. 4. 3β-Phenyltropane-2-carboxylic esters and analogs. J Med Chem 1973; 16: 1260-1267.
53. Asenbaum S, Brücke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38: 1-6.
54. Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998; 29: 128-141.
55. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
56. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71.
57. 123I]β-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol 1998; 39: 44-48.
58. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13: 16-19.
59. 123I]FP-CIT SPECT in healthy controls and early stage, drug-naive Parkinson's disease. J Nucl Med 1998; 39: 1143-1148.
60. 123I-IBZM-SPECT scanning in levodopanaive Parkinson's disease. Mov Disord 1998; 13: 438-445.
61. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982-994.
62. Kuikka JT, Bergström KA, Ahonen A, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995; 22: 356-360.
63. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996; 37: 1129-1133.
64. 11C]β-CFT in early Parkinson's disease. Synapse 1995; 21: 97-103.
65. 11C]β-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 1997; 24: 621-627.
66. 11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolic studies, and positron emission tomography examinations. Nucl Med Biol 1995; 22: 905-913.
67. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic mono-aminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996; 40: 873-874.
68. Bohnen NI, Meyer P, Albin S, et al. Clinical correlates of striatal (+)-[C-11]DTBZ binding to VMAT2 in Parkinson's disease [abstract]. J Nucl Med 1998; 39: 15.
69. 2-like dopamine receptors in human brain. In: Niznik HB, ed. Dopamine receptors and transporters: pharmacology, structure, and function. New York: Marcel Dekker; 1994: 345-383.
70. 2 receptors with SPECT: studies in patients with extrapyramidal disorders and under neuroleptic treatment. J Cereb Blood Flow Metab 1991; 11: 220-228.
71. 11C-raclopride positron emission tomography in previous untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2 receptors. Neurology 1994; 44: 1325-1329.
72. Knable MB, Jones DW, Coppola R. et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 1995; 36: 1216-1225.
73. Fearnley, Lees AJ. Striatonigral-degeneration: a clinico-pathological study. Brain 1990; 113: 1823-1842.
74. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to the rate of clinical symptomatology. Brain 1996; 119: 235-243.
75. Spokes EGS, Bannister R, Oppenheimer DR. Multiple system atrophy with autonomic failure. Clinical, histological and neurochemical observations on four cases. J Neurol Sci 1979; 43: 59-62.
76. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57: 278-284.
77. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120: 2187-2195.
78. 123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressieve supranuclear palsy. J Neural Transm [Suppl] 1997; 50: 9-24.
79. Churchyard A, Donnan GA, Hughes A, et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 1993; 34: 219-226.
80. 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-192.
81. 123I-IBZM single photon emission computed tomography. Arch Neurol 1993; 50: 513-516.
82. 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-1056.
83. Kish SJ, Chang LJ, Mirchandani L, et al. Progressive supranuclear palsy: relationship between extrapyraminal disturbances, dementia, and brain neurotransmitters markers. Ann Neurol 1985; 18: 536.
84. Ruberg M, Javoy-Agid F, Hirsh E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985; 18: 523-529.
85. 3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 1984; 99: 167-175.
86. Pascual J, Berciano J, Grijalba B, et al. Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study. Ann Neurol 1992; 32: 703-707.
87. Nygaard TG. Dopa-responsive dystonia: delineation of the clinical syndrome and clues to the pathogenesis. Adv Neurol 1993;60:577-585.
88. Nygaard TG, Takahashi H, Heiman GA, Snow BJ, Fahn S, Calne DB. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. Ann Neurol 1992; 32: 603-608.
89. Ichinose H, Ohye T, Takahashi E-I, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8: 236-242.
90. Rajput AH, Gibb WRG, Zhong XH, et al. Dopa-responsive dystonia: pathological and biochemical observations in a case. Ann Neurol 1994; 35: 396-402.
91. Nygaard TG, Duvoison RS, Marsden CD. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991; 41: 174-181.
92. 18F]dopa positron emission tomography. Ann Neurol 1991; 30: 24-30.
93. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 1993; 34: 733-738.
94. Nygaard TG. Dopa-responsive dystonia. In: Tsui JKC, Calne DB, eds. Handbook of dystonia. New York: Marcel Dekker; 1995: 213-226.
95. 123I]β-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998; 43: 792-800.
96. 11C]-raclopride and positron-emission tomography. Neurology 1998; 50: 1028-1032.
97. 123I]β-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord 1997; 12: 448-451.
98. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17: 162-174.
99. Wolters EC, Huang CC, Clark D, et al. Positron emission tomography in manganese intoxication. Ann Neurol 1989; 26: 674-651.
100. Shinotoh H, Snow BJ, Chu N-S, et al. Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication: a positron emission tomography study. Neurology 1997; 48: 1053-1056.
101. Calne CB, Langston JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985; 317: 246-248.
102. Vingerhoets FJG, Snow BJ, Tetrud JW, et al. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994; 36: 765-770.
103. Pezzoli G, Antonini A, Barbieri S, et al. n-Hexane-induced parkinsonism: pathogenetic hypotheses. Mov Disord 1995; 10: 279-282.
104. 18F-dopa PET study. Neurology 1997; 49: 183-189.
105. Findley LJ, Büttner. Tremor. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C, eds. Neurological disorders: course and treatment. San Diego: Academic Press; 1996: 853-860.
106. Koller WC, Vetere-Overfield B, Barter R. Tremors in early Parkinson's disease. Clin Neuropharmacol 1989; 12: 293-297.
107. 18F-dopa PET study. Neurology 1992; 42: 1554-1560.
108. 123I]β-CIT and SPECT in the diagnosis of movement disorders. In: de Deyn PP, Dierckx RA, Alavi A, Pickut BA, eds. SPECT in neurology and psychiatry. London: John Libbey; 1997: 187-194.
109. Morrish PK, Rakshi JS, Brooks JD. Can the neuroprotective efficacy of an agent ever be conclusively proven? Eur J Neurol 1997; 4 Suppl 3: S19-S24.
110. Parkes JD, DeBono AG, Marsden CD. Bromocriptine in parkinsonism: long-term treatment, dose response and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976; 26: 1101-1108.
111. Marsden CD, Parkes JD. Success and problems with long-term levodopa treatment in Parkinson's disease. Lancet 1977; 8007: 345-349.
112. Lieberman AN, Gopinathan G, Neophytides A, et al. Bromocriptine and lisuride in Parkinson's disease. Ann Neurol 1983; 13: 44-47.
113. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated with long term levodopa: role of early treatment and disease progression. Neurology 1991; 41: 380-384.
114. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519-522.
115. The Parkinson study group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
116. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 1993; 60: 243-250.
117. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-DOPA on dopaminergic cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993; 8: 129-133.
118. Bhatt MH, Snow BJ, Martin WRW, Pate BD, Ruth TJ, Calne DB. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 1991; 29: 673-677.
119. Vingerhoets FJG, Snow BJ, Lee S, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994; 36: 759-764.
120. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-319.
121. Kurner M, Tatsch K, Linke R, et al. Monitoring the intraindividual progression of Parkinson's disease with [I-123]IPT and SPECT [abstract]. J Nucl Med 1998; 39: 14.
122. 123I]N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol 1995; 22: 211-219.
123. 123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse 1992; 11: 134-139.
124. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295-309.
125. 125I]RTI-55. Synapse 1994; 16: 263-268.
126. 125RTI-55: in vitro binding and autographic characterization. J Neurochem 1994; 62: 549-556.
127. Neumeyer JL, Tamagnan G, Wang S, et al. N-substituted analogs of 2β-carbomethoxy-3β-(4'-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996; 39: 543-548.
128. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997; 27: 183-190.
129. Kuikka JT, Baulieu JL, Hiltunen J, et al. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. Eur J Nucl Med 1998; 25: 531-534.
130. Kung HF, Kim H-J, Kung M-P, Meegalla SK, Plössl K, Lee H-K. Imaging of dopamine transporters in humans with technetium-99 m TRODAT-1. Eur J Nucl Med 1996; 23: 1527-1530.
131. Madras BK, Jones AG, Mahmood A, et al. Technepine: a high affinity technetium-99 m probe to label the dopamine transporter in brain by SPECT imaging. Synapse 1996; 22: 239-246.
132. 99mTc]TRODAT-1: a novel technetium-99 m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997; 24: 372-380.